Literature DB >> 33574310

Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations.

Jacob T Martin1,2, Christopher A Cottrell2,3, Aleksandar Antanasijevic2,3, Diane G Carnathan2,4,5, Benjamin J Cossette1,2, Chiamaka A Enemuo4,5, Etse H Gebru4,5, Yury Choe4,5, Federico Viviano4,5, Stephanie Fischinger6,7, Talar Tokatlian1,2, Kimberly M Cirelli2,8, George Ueda9,10, Jeffrey Copps3, Torben Schiffner2,11, Sergey Menis2,11, Galit Alter6, William R Schief2,6,11, Shane Crotty2,8,12, Neil P King9,10, David Baker9,10,13, Guido Silvestri2,4,5, Andrew B Ward14,15,16, Darrell J Irvine17,18,19,20,21,22.   

Abstract

Following immunization, high-affinity antibody responses develop within germinal centers (GCs), specialized sites within follicles of the lymph node (LN) where B cells proliferate and undergo somatic hypermutation. Antigen availability within GCs is important, as B cells must acquire and present antigen to follicular helper T cells to drive this process. However, recombinant protein immunogens such as soluble human immunodeficiency virus (HIV) envelope (Env) trimers do not efficiently accumulate in follicles following traditional immunization. Here, we demonstrate two strategies to concentrate HIV Env immunogens in follicles, via the formation of immune complexes (ICs) or by employing self-assembling protein nanoparticles for multivalent display of Env antigens. Using rhesus macaques, we show that within a few days following immunization, free trimers were present in a diffuse pattern in draining LNs, while trimer ICs and Env nanoparticles accumulated in B cell follicles. Whole LN imaging strikingly revealed that ICs and trimer nanoparticles concentrated in as many as 500 follicles in a single LN within two days after immunization. Imaging of LNs collected seven days postimmunization showed that Env nanoparticles persisted on follicular dendritic cells in the light zone of nascent GCs. These findings suggest that the form of antigen administered in vaccination can dramatically impact localization in lymphoid tissues and provides a new rationale for the enhanced immune responses observed following immunization with ICs or nanoparticles.

Year:  2020        PMID: 33574310     DOI: 10.1038/s41541-020-00223-1

Source DB:  PubMed          Journal:  NPJ Vaccines        ISSN: 2059-0105            Impact factor:   7.344


  72 in total

1.  Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer.

Authors:  Dmitry Lyumkis; Jean-Philippe Julien; Natalia de Val; Albert Cupo; Clinton S Potter; Per-Johan Klasse; Dennis R Burton; Rogier W Sanders; John P Moore; Bridget Carragher; Ian A Wilson; Andrew B Ward
Journal:  Science       Date:  2013-10-31       Impact factor: 47.728

2.  Crystal structure of a soluble cleaved HIV-1 envelope trimer.

Authors:  Jean-Philippe Julien; Albert Cupo; Devin Sok; Robyn L Stanfield; Dmitry Lyumkis; Marc C Deller; Per-Johan Klasse; Dennis R Burton; Rogier W Sanders; John P Moore; Andrew B Ward; Ian A Wilson
Journal:  Science       Date:  2013-10-31       Impact factor: 47.728

3.  HUMORAL IMMUNITY. T cell help controls the speed of the cell cycle in germinal center B cells.

Authors:  Alexander D Gitlin; Christian T Mayer; Thiago Y Oliveira; Ziv Shulman; Mathew J K Jones; Amnon Koren; Michel C Nussenzweig
Journal:  Science       Date:  2015-07-16       Impact factor: 47.728

4.  Developing an HIV vaccine.

Authors:  Barton F Haynes; Dennis R Burton
Journal:  Science       Date:  2017-03-16       Impact factor: 47.728

Review 5.  HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2018-05-15       Impact factor: 31.745

6.  Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.

Authors:  Matthias Pauthner; Colin Havenar-Daughton; Devin Sok; Joseph P Nkolola; Raiza Bastidas; Archana V Boopathy; Diane G Carnathan; Abishek Chandrashekar; Kimberly M Cirelli; Christopher A Cottrell; Alexey M Eroshkin; Javier Guenaga; Kirti Kaushik; Daniel W Kulp; Jinyan Liu; Laura E McCoy; Aaron L Oom; Gabriel Ozorowski; Kai W Post; Shailendra K Sharma; Jon M Steichen; Steven W de Taeye; Talar Tokatlian; Alba Torrents de la Peña; Salvatore T Butera; Celia C LaBranche; David C Montefiori; Guido Silvestri; Ian A Wilson; Darrell J Irvine; Rogier W Sanders; William R Schief; Andrew B Ward; Richard T Wyatt; Dan H Barouch; Shane Crotty; Dennis R Burton
Journal:  Immunity       Date:  2017-06-20       Impact factor: 31.745

7.  Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques.

Authors:  Amelia Escolano; Harry B Gristick; Morgan E Abernathy; Julia Merkenschlager; Rajeev Gautam; Thiago Y Oliveira; Joy Pai; Anthony P West; Christopher O Barnes; Alexander A Cohen; Haoqing Wang; Jovana Golijanin; Daniel Yost; Jennifer R Keeffe; Zijun Wang; Peng Zhao; Kai-Hui Yao; Jens Bauer; Lilian Nogueira; Han Gao; Alisa V Voll; David C Montefiori; Michael S Seaman; Anna Gazumyan; Murillo Silva; Andrew T McGuire; Leonidas Stamatatos; Darrell J Irvine; Lance Wells; Malcolm A Martin; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Nature       Date:  2019-05-29       Impact factor: 49.962

8.  HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.

Authors:  Rogier W Sanders; Marit J van Gils; Ronald Derking; Devin Sok; Thomas J Ketas; Judith A Burger; Gabriel Ozorowski; Albert Cupo; Cassandra Simonich; Leslie Goo; Heather Arendt; Helen J Kim; Jeong Hyun Lee; Pavel Pugach; Melissa Williams; Gargi Debnath; Brian Moldt; Mariëlle J van Breemen; Gözde Isik; Max Medina-Ramírez; Jaap Willem Back; Wayne C Koff; Jean-Philippe Julien; Eva G Rakasz; Michael S Seaman; Miklos Guttman; Kelly K Lee; Per Johan Klasse; Celia LaBranche; William R Schief; Ian A Wilson; Julie Overbaugh; Dennis R Burton; Andrew B Ward; David C Montefiori; Hansi Dean; John P Moore
Journal:  Science       Date:  2015-06-18       Impact factor: 47.728

9.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

10.  HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.

Authors:  Jon M Steichen; Daniel W Kulp; Talar Tokatlian; Amelia Escolano; Pia Dosenovic; Robyn L Stanfield; Laura E McCoy; Gabriel Ozorowski; Xiaozhen Hu; Oleksandr Kalyuzhniy; Bryan Briney; Torben Schiffner; Fernando Garces; Natalia T Freund; Alexander D Gitlin; Sergey Menis; Erik Georgeson; Michael Kubitz; Yumiko Adachi; Meaghan Jones; Andrew A Mutafyan; Dong Soo Yun; Christian T Mayer; Andrew B Ward; Dennis R Burton; Ian A Wilson; Darrell J Irvine; Michel C Nussenzweig; William R Schief
Journal:  Immunity       Date:  2016-09-08       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.